Clinical trials and observational studies have demonstrated that omalizumab is safe and effective for treating pediatric asthma. However, further research must be conducted to determine the potential benefits of anti-IgE therapy, identify more biomarkers of clinical response, and address unmet needs such as age restrictions on use of omalizumab.

Physicians are facing the challenge to provide a tailored approach to treating patients with severe pediatric asthma, focusing on the diverse pathomechanisms underlying clinical presentations. Severe pediatric asthma represents a heterogeneous disease with multiple clinical phenotypes and is associated with significant morbidity. Th2 inflammation asthma with elevated IgE is the most prevalent endotype of airway inflammation in pediatric asthma. While neutrophilic and paucigranulocytic inflammation patterns are uncommon in patients with pediatric asthma. Considering the pivotal role of IgE in type Th2 inflammation asthma, the blockade of IgE using anti-IgE therapy represents a potent therapeutic option for severe pediatric asthma in children.